Page 126 - 《中国药房》2025年4期

[18] ITO N，YABE T，GAMO Y，et al. I.c.v. administration of S217-S218.
orexin-A induces an antidepressive-like effect through [31] HELLMANN J，DRABEK M，YIN J，et al. Structure-
hippocampal cell proliferation[J]. Neuroscience，2008，157 based development of a subtype-selective orexin 1 recep‐
（4）：720-732. tor antagonist[J]. Proc Natl Acad Sci USA，2020，117
[19] YAEGER J D W，KRUPP K T，JACOBS B M，et al. （30）：18059-18067.
Orexin 1 receptor antagonism in the basolateral amygdala [32] KAUFMANN P，ORT M，GOLOR G，et al. Multiple-dose
shifts the balance from pro- to antistress signaling and clinical pharmacology of the selective orexin-1 receptor
behavior[J]. Biol Psychiatry，2022，91（9）：841-852. antagonist ACT-539313[J]. Prog Neuropsychopharmacol
[20] SALVADORE G，BONAVENTURE P，SHEKHAR A，et Biol Psychiatry，2021，108：110166.
al. Translational evaluation of novel selective orexin-1 [33] STEPAN A F，KIM S H. CVN766，the selective orexin-1-
receptor antagonist JNJ-61393215 in an experimental receptor antagonist progressed to clinical investigations
model for panic in rodents and humans[J]. Transl Psychiatry， [J]. Synfacts，2024，20（5）：531.
2020，10（1）：308. [34] RECOURT K，DE BOER P，ZUIKER R，et al. The selec‐
[21] WANG D，LI A，DONG K Y，et al. Lateral hypothalamus tive orexin-2 antagonist seltorexant（JNJ-42847922/MIN-
orexinergic inputs to lateral habenula modulate maladapta‐ 202）shows antidepressant and sleep-promoting effects in
tion after social defeat stress[J]. Neurobiol Stress，2021， patients with major depressive disorder[J]. Transl Psychia‐
14：100298. try，2019，9（1）：216.
[22] STATON C D，YAEGER J D W，KHALID D，et al. [35] SAVITZ A，WAJS E，ZHANG Y，et al. Efficacy and
Orexin 2 receptor stimulation enhances resilience，while safety of seltorexant as adjunctive therapy in major depres‐
orexin 2 inhibition promotes susceptibility，to social sive disorder：a phase 2b，randomized，placebo-controlled，
stress，anxiety and depression[J]. Neuropharmacology， adaptive dose-finding study[J]. Int J Neuropsychopharma‐
2018，143：79-94. col，2021，24（12）：965-976.
[23] LI B，CHANG L L，PENG X C. Orexin 2 receptor in the [36] UĞURLU M. Orexin receptor antagonists as adjunct
nucleus accumbens is critical for the modulation of acute drugs for the treatment of depression：a mini meta-analysis
stress-induced anxiety[J]. Psychoneuroendocrinology，2021， [J]. Noro Psikiyatr Ars，2023，61（1）：77-84.
131：105317. [37] SEREFKO A，WRÓBEL J，SZOPA A，et al. The orexin
[24] NOLLET M，GAILLARD P，MINIER F，et al. Activation OX2 receptor-dependent pathway is implicated in the
of orexin neurons in dorsomedial/perifornical hypothala‐ development of overactive bladder and depression in rats
mus and antidepressant reversal in a rodent model of exposed to corticosterone[J]. Neurourol Urodyn，2025，44
depression[J]. Neuropharmacology，2011，61 （1/2） ： （1）：229-244.
336-346. [38] 刘晓盈，倪文骐. 食欲素受体拮抗剂治疗失眠的研究进
[25] NOLLET M，GAILLARD P，TANTI A，et al. Neurogenesis- 展[J]. 中国临床保健杂志，2023，26（1）：140-144.
independent antidepressant-like effects on behavior and LIU X Y，NI W Q. Orexin receptor antagonists：a new
stress axis response of a dual orexin receptor antagonist in option for insomnia[J]. Chin J Clin Healthc，2023，26（1）：
a rodent model of depression[J]. Neuropsychopharmaco- 140-144.
logy，2012，37（10）：2210-2221. [39] ISHIBASHI Y，NISHITANI R，SHIMURA A，et al. Cor‐
[26] FANG H，TU S，SHENG J F，et al. Depression in sleep rection：non-GABA sleep medications，suvorexant as risk
disturbance：a review on a bidirectional relationship， factors for falls：case-control and case-crossover study[J].
mechanisms and treatment[J]. J Cell Mol Med，2019，23 PLoS One，2021，16（10）：e0259430.
（4）：2324-2332. [40] GORKA S M，KHORRAMI K J，MANZLER C A，et al.
[27] WANG L，WANG R，SONG M，et al. Association between Acute orexin antagonism selectively modulates anticipa‐
peripheral orexin A/B levels and depression with childhood tory anxiety in humans：implications for addiction and
trauma[J]. J Affect Disord，2023，340：592-597. anxiety[J]. Transl Psychiatry，2022，12（1）：308.
[28] AKÇA Ö F，UZUN N，KıLıNÇ İ. Orexin A in adolescents [41] SHIGETSURA Y，IMAI S，ENDO H，et al. Assessment of
with anxiety disorders[J]. Int J Psychiatry Clin Pract， suvorexant and eszopiclone as alternatives to benzodiaze-
2020，24（2）：127-134. pines for treating insomnia in patients with major depres‐
[29] LI H M，LU J，LI S D，et al. Increased hypocretin（orexin） sive disorder[J]. Clin Neuropharmacol，2022，45（3）：
plasma level in depression，bipolar disorder patients[J]. 52-60.
Front Psychiatry，2021，12：676336. [42] CARPI M，PALAGINI L，FERNANDES M，et al. Clinical
[30] SALVADORE G，BROOKS S，CATHY B，et al. Safety， usefulness of dual orexin receptor antagonism beyond
tolerability，pharmacokinetic and pharmacodynamic pro- insomnia：neurological and psychiatric comorbidities[J].
perties of the selective orexin-1 receptor antagonist JNJ- Neuropharmacology，2024，245：109815.
61393215：results from the first-in-human and multiple as‐ （收稿日期：2024-09-24 修回日期：2025-01-21）
cending dose studies[J]. Biol Psychiatry，2019，85（10）： （编辑：邹丽娟）

· 500 · China Pharmacy 2025 Vol. 36 No. 4 中国药房 2025年第36卷第4期